Dose Insider / Glossary / STEP-HFpEF

STEP-HFpEFSemaglutide for heart failure with preserved ejection fraction

Updated November 20, 2026 路 3 min read 路 Kosiborod et al., N Engl J Med 2023

STEP-HFpEF is the trial of semaglutide in people with obesity and heart failure with preserved ejection fraction, a form of heart failure in which the heart's pumping fraction is normal.

+16.6Semaglutide 2.4 mg, symptom score gain, 52 weeks
Symptom score gain, 52 weeksKCCQ clinical summary, points of 100Semaglutide 2.4 mg+16.6Placebo+8.7Symptom score gain, 52 weeksKCCQ clinical summary, points of 100Semaglutide 2.4 mg+16.6Placebo+8.7

Weight fell 13.3% on semaglutide against 2.6% on placebo.

On this page

It enrolled 529 people with a body mass index of 30 or more and gave them semaglutide 2.4 mg or placebo once a week for 52 weeks. Symptoms and physical limits improved more on semaglutide, and people walked farther. Its authors note that this kind of heart failure is becoming more common, weighs heavily on symptoms and daily function, especially in people with obesity, and that no therapy had been approved to target its obesity-related form. It was published in the New England Journal of Medicine in 2023.1

How the trial was run

The trial had two main outcomes measured together. The first was the clinical summary score of the Kansas City Cardiomyopathy Questionnaire, or KCCQ-CSS, a standard questionnaire scored from 0 to 100 in which higher scores mean fewer symptoms and physical limitations. The second was the change in body weight. Confirmatory secondary outcomes included the distance walked in 6 minutes and a combined ranking of deaths, heart failure events and the other measures.1

What it found

Kosiborod et al., 2023.1

How to read the result

A gain of 7.8 points over placebo on a 100-point symptom scale is a measure of how people felt and what they could do, not of survival or hospital stays. The trial was not designed or large enough to show an effect on deaths or heart failure admissions on their own; those enter only through the combined ranking. Fewer serious adverse events on semaglutide, half the share on placebo, is an encouraging sign about safety in this group.1

The weight loss, 13.3%, was in line with what semaglutide 2.4 mg achieved in other trials, such as 14.9% over 68 weeks in STEP 1, though this trial was shorter.2

Is it on the label?

The Wegovy label's approved uses are weight management, reduction of heart attack, stroke and cardiovascular death in adults with heart disease and excess weight, and a form of fatty liver disease. Heart failure with preserved ejection fraction is not listed as a separate use.3 People with this condition who take Wegovy do so under the weight or heart-risk indications. A related trial of tirzepatide, SUMMIT, studied the same condition in 731 people over a median of 104 weeks. It went a step further: cardiovascular death or a worsening heart failure event occurred in 9.9% on tirzepatide against 15.3% on placebo, a hazard ratio of 0.62, driven mainly by fewer worsening heart failure events, 8.0% against 14.2%.4

Limits

The trial lasted one year and enrolled 529 people, all with a body mass index of 30 or more, so it gives a clear answer about symptoms and function but not about long-term outcomes. Everyone had obesity, with a body mass index of 30 or more; the result may not apply to people with this kind of heart failure and lower weight. It was funded by Novo Nordisk.1 Our page on nausea on a GLP-1 covers the most common side effect.

Sources

  1. Kosiborod MN, Abildstr酶m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med 2023;389:1069-1084. Funded by Novo Nordisk; NCT04788511. doi:10.1056/NEJMoa2306963
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
  4. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med 2025;392:427-437. Funded by Eli Lilly. doi:10.1056/NEJMoa2410027

Related analyses

Log your weight, symptoms and walks and see how they change together.

Open Dose Insider